ArticleMarine drugs2019
The Pharmacokinetics of Fucoidan after Topical Application to Rats.
Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 74 citations in OpenAlex.
- Therapeutic role of fucoidans against oxidative stress: recent developments, translational challenges, and future directions.Archives of toxicology · 2026Review
- Plant-Based Biomaterials as Bio-Instructive Immunomodulators: Design Principles, Mechanisms, and Translational Challenges.Life (Basel, Switzerland) · 2026Review
- The Beneficial Effects of Marine Plant-Derived Compounds on the Musculoskeletal System.International journal of molecular sciences · 2026Review
- Anti-Inflammatory and Neuroprotective Effects ofMarine drugs · 2025Review
- Article
- Investigating the Anti-Inflammatory Activity of Various Brown Algae Species.Marine drugs · 2024Review
- Review
- Effect of Seaweed-Derived Fucoidans fromToxins · 2024Article
- From Ocean to Medicine: Harnessing Seaweed's Potential for Drug Development.International journal of molecular sciences · 2024Review
- Article
- Novel Fucoidan Pharmaceutical Formulations and Their Potential Application in Oncology-A Review.Polymers · 2023Review
- Fucoidan fromMarine drugs · 2023Article
- Fucoidan in Pharmaceutical Formulations: A Comprehensive Review for Smart Drug Delivery Systems.Marine drugs · 2023Review
- Evaluating the Skin Interactions and Permeation of Alginate/Fucoidan HydrogelsPharmaceutics · 2023Article
- A Review on Fucoidan Structure, Extraction Techniques, and Its Role as an Immunomodulatory Agent.Marine drugs · 2022Review
- Structural Characterization and In Vivo Anti-Inflammatory Activity of Fucoidan fromMarine drugs · 2022Article
- Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug-A Review.Molecules (Basel, Switzerland) · 2022Review
- Sulfated Galactofucans: An Outstanding Class of Fucoidans with Promising Bioactivities.Marine drugs · 2022Review
- An Overview of Potential Seaweed-Derived Bioactive Compounds for Pharmaceutical Applications.Marine drugs · 2022Review
- Preclinical Pharmacokinetics, Biodistribution, and Acute Toxicity Evaluation of Caerin 1.9 Peptide in Sprague Dawley Rats.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidan, a fucose-rich polysaccharide from brown algae, has been used for transdermalformulations targeting inflammatory skin conditions, for the treatment of thrombosis, vascularpermeability diseases, subcutaneous wounds, and burns. However, the pharmacokinetics offucoidan after topical application has not been described. In this study, an ointment (OF)containing 15% fucoidan was topically applied to rats at the doses of 50-150 mg/g. The anti-Xaactivity was selected as the biomarker, and the amidolytic assay method was validated and appliedfor pharmacokinetic studies of fucoidan. Fucoidan in OF penetrated the skin and distributed intothe skin, striated muscle, and plasma with AUC0-48 = 0.94 μg·h/g, 2.22 μg·h/g, and 1.92 μg·h/mL,respectively. The longest half-life for fucoidan was observed in plasma, then in striated muscle andskin. It was found that the pharmacokinetics of fucoidan after topical OF application was linear, inthe range of 50-150 mg/kg. No accumulation of fucoidan in plasma was observed after repeatedtopical applications of 100 mg/kg during five days. Our results support the rationality of topicalapplication of formulations with fucoidan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.